FdaApplication
NDA 214120
Identifiers
- fda_app_no: NDA214120
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2020-09-01 |
Revenue by product
ONUREG
| Period | Revenue |
|---|---|
| Q4 2023 | $47.0M |
| Q3 2023 | $43.0M |
| Q2 2023 | $44.0M |
| Q1 2023 | $34.0M |
| Q4 2022 | $37.0M |
| Q3 2022 | $32.0M |
| Q2 2022 | $32.0M |
| Q1 2022 | $23.0M |
| Q4 2021 | $25.0M |
| Q3 2021 | $21.0M |
| Q2 2021 | $12.0M |
| Q1 2021 | $15.0M |
| Q4 2020 | $14.0M |
| Q3 2020 | $3.0M |
| Q2 2020 | $0.0M |
| Q1 2020 | $0.0M |
| Q4 2019 | $0.0M |
| Q3 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ONUREG | AZACITIDINE | 300MG | TABLET;ORAL |
| ONUREG | AZACITIDINE | 200MG | TABLET;ORAL |
2 products